Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 8/20 | 0.51 |
| ▸ | MKNK1 | Q9BUB5 | 11/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16010503 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16009435 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16017030 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16017029 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16009436 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16009433 | 1.00 | PIK3CD (0.51) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16010270 | 0.95 | PIM1 (0.57) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16010269 | 0.95 | PIM1 (0.57) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL16010441 | 0.95 | PIM1 (0.57) | PIK3CDPIK3R1PIM1MKNK1KCNH2 | |
| SCHEMBL2947958 | 0.88 | MKNK1 (0.63) | PIK3CDPIK3R1PIM1MKNK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. | 2016-08-11 | — | — | US | disclosed |
| US-9370515-B2 | Mixed lineage kinase inhibitors and method of treatments | Califia Bio, Inc. (US) | 2016-06-21 | — | — | US | disclosed |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | Califia Bio, Inc. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228437-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIK3CD 316/4885PIK3R1 436/4885PIM1 363/4885 |
| US-20140256733-A1 | MIXED LINEAGE KINASE INHIBITORS AND METHOD OF TREATMENTS | MAP3K2, MAP3K1, MAP3K20 | PIK3CD 316/4885PIK3R1 436/4885PIM1 363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.